Sfoglia per Autore
The BCR-ABL Transcript Levels At 3 and 6 Months Predict the Long-Term Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Imatinib Mesylate: A Gimema CML WP Analysis.
2012-01-01 Fausto Castagnetti; Gabriele Gugliotta; Massimo Breccia; Giorgina Specchia; Elisabetta Abruzzese; Luciano Levato; Francesco Cavazzini; Alessandra Iurlo; Fabio Stagno; Dario Ferrero; Ferdinando Porretto; Bruno Martino; Serena Rupoli; Tamara Intermesoli; Carmen Fava; Francesca Palandri; Claudia Venturi; Simona Soverini; Nicoletta Testoni; Giuliana Alimena; Fabrizio Pane; Giuseppe Saglio; Giovanni Martinelli; Michele Baccarani; and Gianantonio Rosti.
A Retrospective Real-Life Analysis of Chronic Myeloid Leukemia Patients in Suboptimal Response to Imatinib.
2012-01-01 Dario Ferrero; Elena Crisà; Marco Cerrano; Mario Boccadoro; Francesca Pirillo; Maura Nicolosi; Umberto Vitolo; Giovanna Rege Cambrin; Carmen Fava; Giuseppe Saglio; Monia Lunghi; Gioacchino Catania; Alessandro Levis; and Patrizia Pregno.
Moderate/ Severe Pleural Effusion As a Side Effect in Very Old Chronic Myeloid Leukemia (CML) Patients Undergoing Imatinib Treatment.
2011-01-01 Dario Ferrero; Roberto Latagliata; Malgorzata Monika Trawinska; Francesco Cavazzini; Gabriele Gugliotta; Massimo Breccia; Mario Annunziata; Paolo Vigneri; Mario Tiribelli; Gianni Binotto; Carmen Fava; Elena Crisà; Giovanna Mansueto; Antonella Gozzini; Laura Cavalli; Raffaele Porrini; Alessandra Iurlo; Sabina Russo; Barbara Anaclerico; Antonella Russo Rossi; Patrizia Pregno; Giuseppe Visani; Isabella Capodanno; Mauro Endri; Antonio Spadea; Gianfranco Giglio; Francesca Celesti; Federica Sorà; Sergio Storti; Ada M D’Addosio; Giovanna Rege Cambrin; Elisabetta Abruzzese; Gianantonio Rosti; Luigiana Luciano; and Giuliana Alimena.
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML WP
2011-01-01 Gugliotta G; Castagnetti F; Palandri F; Breccia M; Intermesoli T; Capucci A; Martino B; Pregno P; Rupoli S; Ferrero D; Gherlinzoni F; Montefusco E; Bocchia M; Tiribelli M; Pierri I; Grifoni F; Marzocchi G; Amabile M; Testoni N; Martinelli G; Alimena G; Pane F; Saglio G; Baccarani M; Rosti G; Gruppo Italiano Malattie Ematologiche dell'Adulto CML Working Party
Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough?
2011-01-01 Roberto Latagliata; Massimo Breccia; Dario Ferrero; Francesco Cavazzini; Malgorzata Monika Trawinska; Fausto Castagnetti; Mario Annunziata; Fabio Stagno; Mario Tiribelli; Silvia Imbergamo; Carmen Fava; Elena Crisà; Giuseppe Pietrantuono; Antonella Gozzini; Franca Falzetti; Enrico Montefusco; Alessandra Iurlo; Caterina Musolino; Michele Cedrone; Antonella Russo Rossi; Patrizia Pregno; Giuseppe Visani; Isabella Capodanno; Mauro Endri; Antonio Spadea; Gianfranco Giglio; Francesca Celesti; Simona Sica; Sergio Storti; Ada M D'Addosio; Giovanna Rege Cambrin; Luigiana Luciano; Elisabetta Abruzzese; Gianantonio Rosti; and Giuliana Alimena.
Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes.
2011-01-01 Falco P; Levis A; Stacchini A; Ciriello MM; Geuna M; Notari P; Omedè P; Pautasso M; Prato G; Strola G; Gioia D; Bonferroni M; Cametti G; Ferrero D; Freilone R; Gaidano G; Marinone C; Marmont F; Pollio B; Salvi F; Saglio G; Girotto M; Piedmont MDS Registry Italy
High Rate of Erythroid Response During Iron Chelation Therapy in a Cohort of 105 Patients Affected by Hematologic Malignancies with Transfusional Iron Overload: An Italian Multicenter Retrospective Study
2011-01-01 D. Cilloni;E. Messa;L. Biale;M. Bonferroni;F. Salvi;M. Lunghi;B. Allione;D. Ferrero;R. Freilone;A. Levis;G. Saglio
Le citopenie dell' anziano
2010-01-01 D Ferrero; E Crisà
Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program.
2010-01-01 Musto P, Maurillo L, Spagnoli A, Gozzini A, Rivellini F, Lunghi M, Villani O, Aloe-Spiriti MA, Venditti A, Santini V; Ad Hoc Italian Cooperative Study Group on Azacitidine in Myelodysplastic Syndromes Acute Leukemias; Ferrero Dario
A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs
2010-01-01 Crisà E; Venturino E; Passera R; Prina M; Schinco P; Borchiellini A; Giai V; Ciocca Vasino MA; Bazzan M; Vaccarino A; Boccadoro M; Ferrero D
IMPACT OF BCR-ABL MUTATIONS ON RESPONSE TO DASATINIB IN ELDERLY CHRONIC MYELOID LEUKEMIA PATIENTS RESISTANT TO IMATINIB
2010-01-01 Tiribelli M; Latagliata R; Breccia M; Luciano L; Castagnetti F; Gozzini A ; Rege Cambrin G; Annunziata M; Stagno F; Pregno P; Albano F; Abruzzese E; Musto P; Sorà F; Ferrero D; Montefusco E; Cavazzini F; Binotto G; Fanin R; Pane F; Rosti G; Santini V; Fava C; Alimena G; Vigneri P
EFFICACY AND SAFETY PROFILE OF DASATINIB IN A SUBSET OF VERY ELDERLY PATIENS WITH CHRONIC MYELOID LEUKEMIA (CML) RESISTANT/INTOLERANT TO IMATINIB
2010-01-01 Cavazzini F; Latagliata R; Stagno F; Fava C; Tiribelli M; Saccenti E; Binotto G; Occhini U; Sica S; Montefusco E; Porrini R; Rosti G; Luciano L; Martino B; Musto P; Abruzzese E; Pregno P; Ferrero D; Feo C;1 Santini V; Breccia M; Alimena G; Gozzini G
COEXISTENCE OF A JAK2 MUTATED CLONE MAY CAUSE HEMATOLOGIC RESISTANCE (HRES) TO TIROSYN-KINASE INHIBITORS (TKI) IN CHRONIC MYELOID LEUKEMIA (CML)
2009-01-01 Fava C; Rege-Cambrin G; Ferrero D; Ulisciani S; Serra A; Giugliano E; Fava M; Gottardi E; Giaretto L; Saglio G
Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes
2009-01-01 Ferrero D; Darbesio A; Giai V; Genuardi M; Dellacasa CM; Sorasio R; Bertini M; Boccadoro M
Increase of telomerase activity and hTERT expression in myelodysplastic syndromes
2009-01-01 Briatore F; Barrera G; Pizzimenti S; Toaldo C; Della Casa CD; Laurora S; Pettazzoni P; Dianzani MU; Ferrero D
CEP-18770: a novel orally-active proteasome inhibitor with a tumor-selective pharmacological profile competitive with bortezomib
2008-01-01 Piva R; Ruggeri B; Williams M;Costa G;Tamagno I; Ferrero D; Giai V; Coscia M; Peola S; Massaia M;Pezzoni G; Allievi C; Pescalli N; Cassin M; di Giovine S; Nicoli P;de Feudis P; Strepponi I; Roato I; Ferracini R; Bussolati B; Camussi G; Jones-Bolin S; Hunter K; Zhao H; Neri A; Palumbo A; Berkers C; Ovaa H; Bernareggi A; Inghirami G
The Degree of Telomere Loss in Hematopoietic Cells Correlates with the Risk of Secondary Myelodysplasia/Acute Leukemia Development Following Autologous Stem Cell Transplantation
2007-01-01 Irene Ricca; Alberto Rocci; Marco Ruella; Manuela Zanni; Daniele Caracciolo; Marco Ladetto; Mario Boccadoro; Dario Ferrero; Corrado Tarella
Long-term lymphoma survivors following high-dose chemotherapy and autograft: evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoir
2007-01-01 ROCCI A; RICCA I; DELLACASA C; LONGONI P; COMPAGNO M; FRANCESE R; LOBETTI BODONI C; MANZINI P; CARACCIOLO D; BOCCADORO M; FERRERO D; LADETTO M; CARLO-STELLA C; TARELLA C
Corticosteroids can reverse severe imatinib-induced hepatotoxicity
2006-01-01 FERRERO D; POGLIANI EM; REGE-CAMBRIN G; FAVA C; MATTIOLI G; DELLACASA C; CAMPA E; PERFETTI P; FUMAGALLI M; BOCCADORO M
A Ph-Negative Myeloproliferative Disorder with JAK2 Mutation Disclosed by Imatinib Therapy in Two Patients with Ph+ CML.
2006-01-01 Emilia Giugliano; Dario Ferrero; Carmen Fava; Chiara Dellacasa; Giovanna Mattioli; Patrizia Scaravaglio; Enrico Gottardi; Stefano Ulisciani; Filomena Daraio; Giuseppe Saglio; Giovanna Rege.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| The BCR-ABL Transcript Levels At 3 and 6 Months Predict the Long-Term Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Imatinib Mesylate: A Gimema CML WP Analysis. | 2012 | Fausto Castagnetti; Gabriele Gugliotta; Massimo Breccia; Giorgina Specchia; Elisabetta Abruzzese; Luciano Levato; Francesco Cavazzini; Alessandra Iurlo; Fabio Stagno; Dario Ferrero; Ferdinando Porretto; Bruno Martino; Serena Rupoli; Tamara Intermesoli; Carmen Fava; Francesca Palandri; Claudia Venturi; Simona Soverini; Nicoletta Testoni; Giuliana Alimena; Fabrizio Pane; Giuseppe Saglio; Giovanni Martinelli; Michele Baccarani; and Gianantonio Rosti. | |
| A Retrospective Real-Life Analysis of Chronic Myeloid Leukemia Patients in Suboptimal Response to Imatinib. | 2012 | Dario Ferrero; Elena Crisà; Marco Cerrano; Mario Boccadoro; Francesca Pirillo; Maura Nicolosi; Umberto Vitolo; Giovanna Rege Cambrin; Carmen Fava; Giuseppe Saglio; Monia Lunghi; Gioacchino Catania; Alessandro Levis; and Patrizia Pregno. | |
| Moderate/ Severe Pleural Effusion As a Side Effect in Very Old Chronic Myeloid Leukemia (CML) Patients Undergoing Imatinib Treatment. | 2011 | Dario Ferrero; Roberto Latagliata; Malgorzata Monika Trawinska; Francesco Cavazzini; Gabriele Gugliotta; Massimo Breccia; Mario Annunziata; Paolo Vigneri; Mario Tiribelli; Gianni Binotto; Carmen Fava; Elena Crisà; Giovanna Mansueto; Antonella Gozzini; Laura Cavalli; Raffaele Porrini; Alessandra Iurlo; Sabina Russo; Barbara Anaclerico; Antonella Russo Rossi; Patrizia Pregno; Giuseppe Visani; Isabella Capodanno; Mauro Endri; Antonio Spadea; Gianfranco Giglio; Francesca Celesti; Federica Sorà; Sergio Storti; Ada M D’Addosio; Giovanna Rege Cambrin; Elisabetta Abruzzese; Gianantonio Rosti; Luigiana Luciano; and Giuliana Alimena. | |
| Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML WP | 2011 | Gugliotta G; Castagnetti F; Palandri F; Breccia M; Intermesoli T; Capucci A; Martino B; Pregno P; Rupoli S; Ferrero D; Gherlinzoni F; Montefusco E; Bocchia M; Tiribelli M; Pierri I; Grifoni F; Marzocchi G; Amabile M; Testoni N; Martinelli G; Alimena G; Pane F; Saglio G; Baccarani M; Rosti G; Gruppo Italiano Malattie Ematologiche dell'Adulto CML Working Party | |
| Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough? | 2011 | Roberto Latagliata; Massimo Breccia; Dario Ferrero; Francesco Cavazzini; Malgorzata Monika Trawinska; Fausto Castagnetti; Mario Annunziata; Fabio Stagno; Mario Tiribelli; Silvia Imbergamo; Carmen Fava; Elena Crisà; Giuseppe Pietrantuono; Antonella Gozzini; Franca Falzetti; Enrico Montefusco; Alessandra Iurlo; Caterina Musolino; Michele Cedrone; Antonella Russo Rossi; Patrizia Pregno; Giuseppe Visani; Isabella Capodanno; Mauro Endri; Antonio Spadea; Gianfranco Giglio; Francesca Celesti; Simona Sica; Sergio Storti; Ada M D'Addosio; Giovanna Rege Cambrin; Luigiana Luciano; Elisabetta Abruzzese; Gianantonio Rosti; and Giuliana Alimena. | |
| Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes. | 2011 | Falco P; Levis A; Stacchini A; Ciriello MM; Geuna M; Notari P; Omedè P; Pautasso M; Prato G; Strola G; Gioia D; Bonferroni M; Cametti G; Ferrero D; Freilone R; Gaidano G; Marinone C; Marmont F; Pollio B; Salvi F; Saglio G; Girotto M; Piedmont MDS Registry Italy | |
| High Rate of Erythroid Response During Iron Chelation Therapy in a Cohort of 105 Patients Affected by Hematologic Malignancies with Transfusional Iron Overload: An Italian Multicenter Retrospective Study | 2011 | D. Cilloni;E. Messa;L. Biale;M. Bonferroni;F. Salvi;M. Lunghi;B. Allione;D. Ferrero;R. Freilone;A. Levis;G. Saglio | |
| Le citopenie dell' anziano | 2010 | D Ferrero; E Crisà | |
| Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program. | 2010 | Musto P, Maurillo L, Spagnoli A, Gozzini A, Rivellini F, Lunghi M, Villani O, Aloe-Spiriti MA, Venditti A, Santini V; Ad Hoc Italian Cooperative Study Group on Azacitidine in Myelodysplastic Syndromes Acute Leukemias; Ferrero Dario | |
| A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs | 2010 | Crisà E; Venturino E; Passera R; Prina M; Schinco P; Borchiellini A; Giai V; Ciocca Vasino MA; Bazzan M; Vaccarino A; Boccadoro M; Ferrero D | |
| IMPACT OF BCR-ABL MUTATIONS ON RESPONSE TO DASATINIB IN ELDERLY CHRONIC MYELOID LEUKEMIA PATIENTS RESISTANT TO IMATINIB | 2010 | Tiribelli M; Latagliata R; Breccia M; Luciano L; Castagnetti F; Gozzini A ; Rege Cambrin G; Annunziata M; Stagno F; Pregno P; Albano F; Abruzzese E; Musto P; Sorà F; Ferrero D; Montefusco E; Cavazzini F; Binotto G; Fanin R; Pane F; Rosti G; Santini V; Fava C; Alimena G; Vigneri P | |
| EFFICACY AND SAFETY PROFILE OF DASATINIB IN A SUBSET OF VERY ELDERLY PATIENS WITH CHRONIC MYELOID LEUKEMIA (CML) RESISTANT/INTOLERANT TO IMATINIB | 2010 | Cavazzini F; Latagliata R; Stagno F; Fava C; Tiribelli M; Saccenti E; Binotto G; Occhini U; Sica S; Montefusco E; Porrini R; Rosti G; Luciano L; Martino B; Musto P; Abruzzese E; Pregno P; Ferrero D; Feo C;1 Santini V; Breccia M; Alimena G; Gozzini G | |
| COEXISTENCE OF A JAK2 MUTATED CLONE MAY CAUSE HEMATOLOGIC RESISTANCE (HRES) TO TIROSYN-KINASE INHIBITORS (TKI) IN CHRONIC MYELOID LEUKEMIA (CML) | 2009 | Fava C; Rege-Cambrin G; Ferrero D; Ulisciani S; Serra A; Giugliano E; Fava M; Gottardi E; Giaretto L; Saglio G | |
| Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes | 2009 | Ferrero D; Darbesio A; Giai V; Genuardi M; Dellacasa CM; Sorasio R; Bertini M; Boccadoro M | |
| Increase of telomerase activity and hTERT expression in myelodysplastic syndromes | 2009 | Briatore F; Barrera G; Pizzimenti S; Toaldo C; Della Casa CD; Laurora S; Pettazzoni P; Dianzani MU; Ferrero D | |
| CEP-18770: a novel orally-active proteasome inhibitor with a tumor-selective pharmacological profile competitive with bortezomib | 2008 | Piva R; Ruggeri B; Williams M;Costa G;Tamagno I; Ferrero D; Giai V; Coscia M; Peola S; Massaia M;Pezzoni G; Allievi C; Pescalli N; Cassin M; di Giovine S; Nicoli P;de Feudis P; Strepponi I; Roato I; Ferracini R; Bussolati B; Camussi G; Jones-Bolin S; Hunter K; Zhao H; Neri A; Palumbo A; Berkers C; Ovaa H; Bernareggi A; Inghirami G | |
| The Degree of Telomere Loss in Hematopoietic Cells Correlates with the Risk of Secondary Myelodysplasia/Acute Leukemia Development Following Autologous Stem Cell Transplantation | 2007 | Irene Ricca; Alberto Rocci; Marco Ruella; Manuela Zanni; Daniele Caracciolo; Marco Ladetto; Mario Boccadoro; Dario Ferrero; Corrado Tarella | |
| Long-term lymphoma survivors following high-dose chemotherapy and autograft: evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoir | 2007 | ROCCI A; RICCA I; DELLACASA C; LONGONI P; COMPAGNO M; FRANCESE R; LOBETTI BODONI C; MANZINI P; CARACCIOLO D; BOCCADORO M; FERRERO D; LADETTO M; CARLO-STELLA C; TARELLA C | |
| Corticosteroids can reverse severe imatinib-induced hepatotoxicity | 2006 | FERRERO D; POGLIANI EM; REGE-CAMBRIN G; FAVA C; MATTIOLI G; DELLACASA C; CAMPA E; PERFETTI P; FUMAGALLI M; BOCCADORO M | |
| A Ph-Negative Myeloproliferative Disorder with JAK2 Mutation Disclosed by Imatinib Therapy in Two Patients with Ph+ CML. | 2006 | Emilia Giugliano; Dario Ferrero; Carmen Fava; Chiara Dellacasa; Giovanna Mattioli; Patrizia Scaravaglio; Enrico Gottardi; Stefano Ulisciani; Filomena Daraio; Giuseppe Saglio; Giovanna Rege. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile